Prostate Cancer Early Detection in the European Union and UK

J 2025

Prostate Cancer Early Detection in the European Union and UK

LEENEN, Renee C A; Lionne D F VENDERBOS; Jozien HELLEMAN; Juan Gomez RIVAS; Pieter VYNCKIER et al.

Základní údaje

Originální název

Prostate Cancer Early Detection in the European Union and UK

Autoři

Vydání

European Urology, Amsterdam, Elsevier, 2025, 0302-2838

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 25.200 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00140939

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Benefits; Early detection; Harms; Mortality; Opportunistic testing; Prostate cancer; Prostate-specific antigen; Screening; Screening behaviour

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2025 08:48, Mgr. Tereza Miškechová

Anotace

V originále

Background and objective: While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK. Methods: On June 1, 2023, we searched four databases (Medline ALL via Ovid, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) and Google Scholar. To avoid repetition of previous studies, only SRs (qualitative, quantitative, and/or MAs) were considered eligible. In the data, common themes were identified to present the evidence systematically. Key findings and limitations: We identified 1358 citations, resulting in 26 SRs eligible for inclusion. Six themes were identified: (1) invitation: men at general risk should be invited at >50 yr of age, and testing should be discontinued at >70 yr or with <10 yr of life expectancy; (2) decision-making: most health authorities discourage population-based screening and instead recommend a shared decision-making (SDM) approach, but implementation of SDM in clinical practice varies widely; decision aids help men make more informed and value-consistent screening decisions and decrease men's intention to attempt screening, but these do not affect screening uptake; (3) acceptance: facilitators for men considering screening include social prompting by partners and clinician recommendations, while barriers include a lack of knowledge, lowrisk perception, and masculinity attributes; (4) screening test and algorithm: prostate specific antigen-based screening reduces PCa-specific mortality and metastatic disease in men aged 55-69 yr at randomisation if screened at least twice; (5) harms and benefits: these benefits come at the cost of unnecessary biopsies, overdiagnosis, and subsequent overtreatment; and (6) future of screening: risk-adapted screening including (prebiopsy) risk calculators, magnetic resonance imaging, and blood- and urine-based biomarkers could reduce these harms. To enable a comprehensive overview, we focused on SRs. These do not include the most recent prospective studies, which were therefore incorporated in the discussion. Conclusions and clinical implications: By identifying consistent and conflicting evidence, this review highlights the evidence-based foundations that can be built upon, as well as areas requiring further research and improvement to reduce the burden of PCa in the EU and UK. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.

Citovat

LEENEN, Renee C A; Lionne D F VENDERBOS; Jozien HELLEMAN; Juan Gomez RIVAS; Pieter VYNCKIER; Lieven ANNEMANS; Renata CHLOUPKOVÁ; Ondřej MÁJEK; Erik BRIERS; Vera VASILYEVA; Sebastiaan REMMERS; Meike J VAN HARTEN; Frederique B DENIJS; Ivo I DE VOS; Arunah CHANDRAN; Partha BASU; Roderick C N VAN DEN BERGH; Sarah COLLEN; Hein Van POPPEL; Monique J ROOBOL a Katharina BEYER. Prostate Cancer Early Detection in the European Union and UK. European Urology. Amsterdam: Elsevier, 2025, roč. 87, č. 3, s. 326-339. ISSN 0302-2838. Dostupné z: https://doi.org/10.1016/j.eururo.2024.07.019.

@article{2488662,
   author = {Leenen, Renee C A and Venderbos, Lionne D F and Helleman, Jozien and Rivas, Juan Gomez and Vynckier, Pieter and Annemans, Lieven and Chloupková, Renata and Májek, Ondřej and Briers, Erik and Vasilyeva, Vera and Remmers, Sebastiaan and van Harten, Meike J and Denijs, Frederique B and de Vos, Ivo I and Chandran, Arunah and Basu, Partha and van den Bergh, Roderick C N and Collen, Sarah and Poppel, Hein Van and Roobol, Monique J and Beyer, Katharina},
   article_location = {Amsterdam},
   article_number = {3},
   doi = {https://doi.org/10.1016/j.eururo.2024.07.019},
   keywords = {Benefits; Early detection; Harms; Mortality; Opportunistic testing; Prostate cancer; Prostate-specific antigen; Screening; Screening behaviour},
   language = {eng},
   issn = {0302-2838},
   journal = {European Urology},
   title = {Prostate Cancer Early Detection in the European Union and UK},
   url = {https://www.sciencedirect.com/science/article/pii/S0302283824025028?via%3Dihub},
   volume = {87},
   year = {2025}
}

TY  - JOUR
ID  - 2488662
AU  - Leenen, Renee C A - Venderbos, Lionne D F - Helleman, Jozien - Rivas, Juan Gomez - Vynckier, Pieter - Annemans, Lieven - Chloupková, Renata - Májek, Ondřej - Briers, Erik - Vasilyeva, Vera - Remmers, Sebastiaan - van Harten, Meike J - Denijs, Frederique B - de Vos, Ivo I - Chandran, Arunah - Basu, Partha - van den Bergh, Roderick C N - Collen, Sarah - Poppel, Hein Van - Roobol, Monique J - Beyer, Katharina
PY  - 2025
TI  - Prostate Cancer Early Detection in the European Union and UK
JF  - European Urology
VL  - 87
IS  - 3
SP  - 326-339
EP  - 326-339
PB  - Elsevier
SN  - 03022838
KW  - Benefits
KW  - Early detection
KW  - Harms
KW  - Mortality
KW  - Opportunistic testing
KW  - Prostate cancer
KW  - Prostate-specific antigen
KW  - Screening
KW  - Screening behaviour
UR  - https://www.sciencedirect.com/science/article/pii/S0302283824025028?via%3Dihub
N2  - Background and objective: While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK. Methods: On June 1, 2023, we searched four databases (Medline ALL via Ovid, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) and Google Scholar. To avoid repetition of previous studies, only SRs (qualitative, quantitative, and/or MAs) were considered eligible. In the data, common themes were identified to present the evidence systematically. Key findings and limitations: We identified 1358 citations, resulting in 26 SRs eligible for inclusion. Six themes were identified: (1) invitation: men at general risk should be invited at >50 yr of age, and testing should be discontinued at >70 yr or with <10 yr of life expectancy; (2) decision-making: most health authorities discourage population-based screening and instead recommend a shared decision-making (SDM) approach, but implementation of SDM in clinical practice varies widely; decision aids help men make more informed and value-consistent screening decisions and decrease men's intention to attempt screening, but these do not affect screening uptake; (3) acceptance: facilitators for men considering screening include social prompting by partners and clinician recommendations, while barriers include a lack of knowledge, lowrisk perception, and masculinity attributes; (4) screening test and algorithm: prostate specific antigen-based screening reduces PCa-specific mortality and metastatic disease in men aged 55-69 yr at randomisation if screened at least twice; (5) harms and benefits: these benefits come at the cost of unnecessary biopsies, overdiagnosis, and subsequent overtreatment; and (6) future of screening: risk-adapted screening including (prebiopsy) risk calculators, magnetic resonance imaging, and blood- and urine-based biomarkers could reduce these harms. To enable a comprehensive overview, we focused on SRs. These do not include the most recent prospective studies, which were therefore incorporated in the discussion. Conclusions and clinical implications: By identifying consistent and conflicting evidence, this review highlights the evidence-based foundations that can be built upon, as well as areas requiring further research and improvement to reduce the burden of PCa in the EU and UK. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.
ER  -

LEENEN, Renee C A; Lionne D F VENDERBOS; Jozien HELLEMAN; Juan Gomez RIVAS; Pieter VYNCKIER; Lieven ANNEMANS; Renata CHLOUPKOVÁ; Ondřej MÁJEK; Erik BRIERS; Vera VASILYEVA; Sebastiaan REMMERS; Meike J VAN HARTEN; Frederique B DENIJS; Ivo I DE VOS; Arunah CHANDRAN; Partha BASU; Roderick C N VAN DEN BERGH; Sarah COLLEN; Hein Van POPPEL; Monique J ROOBOL a Katharina BEYER. Prostate Cancer Early Detection in the European Union and UK. \textit{European Urology}. Amsterdam: Elsevier, 2025, roč.~87, č.~3, s.~326-339. ISSN~0302-2838. Dostupné z: https://doi.org/10.1016/j.eururo.2024.07.019.

Přehled o publikaci